Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial - 18/04/17
Abstract |
Background |
Ingenol mebutate (IngMeb) is approved for treatment of actinic keratoses (AK) and may cause unpredictable local skin responses (LSR).
Objectives |
We sought to investigate whether IngMeb-induced LSR, pain, and pruritus could be alleviated with a topical glucocorticoid and, further, to assess efficacy, cosmetic outcome, and patient satisfaction in patients with severe photodamage.
Methods |
In this blinded, randomized controlled clinical trial, patients with multiple AK and field cancerization of the face or scalp were treated in 2 areas with IngMeb (0.015%) daily for 3 days. After finalized IngMeb treatment, 1 area was randomized to receive topical clobetasol propionate (0.05%) twice daily for 4 days. Assessments included LSR (0-24; days 1, 4, 8, 15, 57), pain (0-10) and pruritus (0-3; days 1-15), AK clearance (days 15, 57), and cosmetic outcome (0-3; day 57).
Results |
Clobetasol propionate application had no influence on LSR (P = .939), pain (P = .500), pruritus (P = .312), or AK cure rate (P = .991). Overall, IngMeb cleared 86% of all AK lesions, exerting a therapeutic effect on all AK severity grades; cure rates were 88%, 70%, and 60% for grade I, II, and III AK, respectively. Skin texture improved significantly in remedied areas (2.0 vs 1.0; P < .001); no hypopigmentation, hyperpigmentation, or scarring were observed.
Limitations |
These results do not provide safety and efficacy beyond 2 months of follow-up.
Conclusion |
Application of clobetasol propionate does not alleviate IngMeb-induced LSR after 3 days of IngMeb treatment.
Le texte complet de cet article est disponible en PDF.Key words : actinic keratoses, actinic keratosis, blinded, clearance, clobetasol, corticosteroid, cosmesis, cosmetic outcome, cure rate, glucocorticoid, hyperkeratotic, inflammation, ingenol mebutate, local skin responses, pain, patient satisfaction, photodamage, pruritus, rejuvenation, skin texture
Abbreviations used : AK, IngMeb, LSR
Plan
This is an investigator-initiated study. Research grant and ingenol mebutate gel provided by Leo Pharma A/S, which had no role in the design, study conduction, or preparation of the manuscript. |
|
Disclosure: Drs Erlendsson and Haedersdal received research grants from Leo Pharma A/S. Drs Karmisholt, Skovbølling Haak, and Stender have no conflicts of interest to declare. |
|
Presented at the 73rd Annual Meeting of the American Academy of Dermatology in San Francisco, CA, March 20-24, 2015. |
Vol 74 - N° 4
P. 709-715 - avril 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?